High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain
Journal Title: Annals of Hepatology - Year 2015, Vol 14, Issue 4
Abstract
Background and rational. Telaprevir-based therapy (TBT) has been extensively evaluated in clinical trials. So we designed a study to compare the efficacy and safety of TBT between patients with moderate fibrosis and those suffering from advanced fibrosis in clinical practice. A multicenter observational and ambispective study was conducted. It included 582 patients with chronic hepatitis C genotype 1, 214 with fibrosis F2, and 368 with F3/F4 (F3: 148; F4: 220). Results. The mean patient age was 55 years, 67% male. Type of prior response was 22% naïve, 57% relapsers, and 21% partial/null responders, 69% had high viral load (> 800,000 IU/mL). HCV genotypes were 1a (19%), 1b (69%), and 1 (12%), respectively. Sixty-five percent were non-CC IL28B genotype. Week-12 sustained virologic response (SVR12) was significantly higher among F2-naïve patients (78%) compared with F3/F4-naïve patients (60%; p = 0.039) and among F2 non-responders (67%) compared with F3/F4 non-responders (42%; p = 0.014). SVR12 among relapsers was remarkably high in both groups (F2:89% vs. F3/F4:78%). Severe anemia and thrombocytopenia were more frequent among patients with F3/F4 than those with F2 (p < 0.01). Overall, 132 patients (22%) discontinued treatment: 58 due to adverse effects, 42 due to the stopping-rule, and 32 due to breakthrough. Premature discontinuation was more frequent among patients with F3/F4 (p = 0.028), especially due to breakthrough (p < 0.001). Conclusions. This multicenter study demonstrates high efficacy and an acceptable safety profile with regard to TBT in F2-patients in clinical practice.
Authors and Affiliations
Javier Crespo, Moisés Diago, Joaquín Cabezas, Marina Berenguer, Teresa Broquetas, Miguel Ángel Serra, Rosa Morillas, José Calleja, Juan Sánchez, Sabela Lens, Susana Soto-Fernández, Begoña Sacristán, Inmaculada Fernández, Carmen López-Núñez, María Buti, Manuel Romero-Gómez, Federico Sáez-Royuela, Conrado Fernández, Francisco Jorquera, Gloria Sánchez-Antolín, Antonio Cuadrado
Keywords
Related Articles
- EP ID EP78473
- DOI -
- Views 108
- Downloads 0
Lipid-bound sialic acid (LSA) in liver diseases of different etiologies
Objective. There are evidences that the changes in glycosylation and sialylation of proteins and lipids play an important role in the pathogenesis and progression of various liver diseases. The aim of this study was to e...
Health-related quality of life in Egyptian patients after liver transplantation
Introduction-Aim. Health-Related Quality of Life (HRQOL) has become an important focus of patient care and clinical outcomes research with the improvement in patient and graft survival after liver transplantation (LT). T...
Efficacy of Probiotics and Smectite in Rats with Non-Alcoholic Fatty Liver Disease
Introduction and aim. Today probiotics have been suggested as a treatment for the prevention of non-alcoholic fatty liver disease (NAFLD). Smectite is a natural silicate that binds to digestive mucous and has the ability...
Is intestinal oxidative stress involved in patients with compensated liver cirrhosis?
Background. Liver cirrhosis is associated with intestinal epithelial barrier dysfunction, which may be affected by oxidative stress.Studies in cirrhotic rats provided evidence for intestinal oxidative stress, but studie...
The role of hepatitis B immunoglobulin in hepatitis B related liver transplantation: Canadian Transplant Centre Position Paper
Introduction. Hepatitis B virus (HBV) related liver transplant (LT) recipients face a high risk of HBV reinfection in the absence of continuous post-operative HBV prophylaxis. Combination HBV prophylaxis with hepatitis B...